Hope For Blood and Bone Cancer Patients: Jeanmarie Guenot’s Lifesaving Work

 

JeanMarie Guenot is the founder and the CEO of Amphivena Therapeutics Inc., a company that develops the treatment for blood and bone cancer. The company was launched in 2012 and was created as a subsidiary of venture-backed Affimed Therapeutics AG; Janssen Biotech is an investor in Amphivena Therapeutics. Since the start, they have made achievement worth noting; in 2015, the company together with Janssen selected a clinical candidate and believed with the candidate they will be able to meet needs of patients with that kind of cancer. 2016 was a good year too because the U.S. Food and Drug Administration accepted their new drug as an investigational drug, this will enable them to know the correct dosage for the patients. The CEO believed the drug would be a therapeutic option for both patients and their doctors. Amphivena Therapeutics has come to the rescue of many hematologic malignancies patients.

With twenty years’ worth of experience, JeanMarie Guenot has worked in many different companies ranging from private to public and in various departments. She has high interest in building and rebuilding companies. Between 2009 and 2012 founder, partner and the first employee of SKS Ocular, LLC; Dr. Guenot was a managing partner of Guenot LLC in 2008 to 2009. Vice President, Corporate and Business Development for PDL BioPharma for five years, Associate at Atlas Venture from 2000 to 2003 and Principal Scientist at Hoffman-La Roche from 1993 to 1999. She has always been an asset in all these organizations she worked, and her impact felt in each.

JeanMarie Guenot attended the University of California, San Francisco and earned a Ph. D, she also has an MBA from the University of Pennsylvania. Dr. Guenot has training in medicinal and physical chemistry having focused in quantum mechanical and semi-empirical methods for molecular dynamics, protein structure prediction, X-ray and NMR refinement and drug design. In 2005 she received an award for BioBusiness Network’s Innovative Bio-Partnering and another in 2006 from licensing executive society, Deal of Distinction. JeanMarie is good at what she does and has earned her lot of respect in the field.

Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies

Leave a Reply